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Abstract
Introduction: Atrial fibrillation affects an estimated 2.5 million Americans and incurs an average
annual stroke risk of 4.5% per year. Despite warfarin reducing stroke risk by approximately 66%,
prior studies show warfarin usage rates to be about 50%. However, the methods that define
warfarin as "inappropriate underutilization" might not be sensitive enough to pick up relative
contraindications. We assessed the inappropriate underutilization of warfarin in atrial fibrillation
patients at our hospital by abstracting individual patient charts.
Methods: Medical records were reviewed to determine stroke risk factors, warfarin use, and
documented contraindications to warfarin use in 364 consecutive patients with atrial fibrillation.
Results: Amongst 364 atrial fibrillation patients, 54.6% received warfarin anticoagulation. Overall,
29.5 % of patients had documented reasons for not prescribing warfarin. Primary reasons listed by
treating physicians included: gastrointestinal bleed 10.7%, secondary/transient atrial fibrillation
8.2%, and fall risk 6.3%. Only 7.1% of the patients had no documented reasons for the lack of
warfarin use.
Conclusion: Consistent with previous reports, 45.4% of patients in this atrial fibrillation cohort
were not prescribed warfarin. However, after reviewing medical charts for documented reasons
why warfarin was not used, the inappropriate underutilization rate was only 7.1%. These findings
suggest that studies utilizing administrative database and ICD-9 CM coding might overestimate
warfarin underutilization.
Introduction
Atrial fibrillation (AF) currently affects an estimated 2.5
million patients in the United States and this number is
expected to double within the next 20 years. [1,2] AF is
particularly prevalent in the elderly population affecting 1
in 10 people over the age of 80 and accounting for one
quarter of all strokes in the elderly population. [1]
Patients with AF not receiving antithrombotic therapy
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have a stroke risk of 4.5% per year. [3-5] While studies
have shown that warfarin therapy could reduce this stoke
risk by about 66%[6], it is distressing to note that warfarin
therapy remains widely underutilized [7-9], with bleeding
risk and monitoring concerns being cited as the most
common reasons for nonuse.
Prior studies analyzing warfarin utilization in patients
with AF have generally relied on administrative data in
determining patient's candidacy for warfarin therapy. [7-
12] Due to the inherent study design and methodology,
warfarin underutilization rates can be overestimated in
such studies by including patients with relative or per-
ceived contraindications to anticoagulation. The objec-
tives of this study were a) To determine the rate of
warfarin underutilization in a cohort of AF patients by ret-
rospectively reviewing medical charts including physician
verification of electrocardiograms (EKG), b) To compare
methodologies of prior studies investigating warfarin
underutilization and the role of chart review in estimating
warfarin underutilization in AF patients and c) Attempt to
identify physician-professed reasoning for not initiating
warfarin therapy and analyze the adequacy of these rea-
sons/contraindications.
Methods
Study Population
We retrospectively reviewed medical records of 364
patients with atrial fibrillation, after EKG confirmation by
a cardiologist, and at least 1 year of follow-up from the
index EKG. Index EKGs were obtained from inpatient and
outpatient data from January 1, 2002, through December
31, 2003. The study was approved by the Henry Ford Hos-
pital Institutional Review Board.
Variables
Electronic medical records were reviewed for stroke risk
factors, which included baseline demographic variables
and previous diagnoses of stroke/transient ischemic attack
(TIA), congestive heart failure (CHF), myocardial infarc-
tion (MI), coronary artery disease (CAD), hypertension,
and diabetes mellitus (DM). Clinic notes and hospital dis-
charge summaries were reviewed to identify physician
documented reasons for not prescribing warfarin therapy.
Patient race/ethnicity was obtained from demographic
profiles listed in electronic medical records. Gastrointesti-
nal bleed was considered to be a limiting factor if there
was a physician note documenting prior history of bleed-
ing or guaiac-positive stools. Non-gastrointestinal bleeds
included bleeding from all other causes, such as
hematoma and trauma. Fall risk was recorded if there was
a physician note stating increased risk for falls or unfavo-
rable fall risk to warfarin benefit ratio. Patients were con-
sidered to have transient or secondary AF if there were
EKGs documenting AF during an acute event, such as sur-
gery or acute medical illness with all subsequent EKGs
showing normal sinus rhythm and physician notes stating
warfarin was not indicated. Patients with a prior diagnosis
of AF that had converted to sinus rhythm during follow-
up were also included in this group. Patient compliance
was considered a factor if there were physician notes stat-
ing that the patient had a previous history of non-compli-
ance to medical therapy. Coagulopathy included patients
with an underlying bleeding or coagulation disorder plac-
ing them at an increased risk for bleeding. CHADS2 (C-
cardiac failure, H-hypertension, A-age > 75 years, D- dia-
betes mellitus, S- stroke) index is a point-based system to
stratify stroke risk and thereby help guide with anti-coag-
ulation decision-making in patients with AF.[3] 2 points
are assigned for previous stroke or TIA and 1 point each
for age > 75 years, hypertension, diabetes mellitus or
recent congestive heart failure. The total score calculated
then helps determine the stroke risk, with higher the
CHADS2 score greater the risk of stroke.
Statistical Analysis
A descriptive analysis was performed to compare baseline
clinical and demographic characteristics between patient
groups receiving warfarin and those not receiving warfa-
rin. The chi-square test was used for categorical variables
and Student's t  test for the continuous variables. The
CHADS2 score between the two groups were compared
using the Wilcoxon rank sum test. After breaking down
the CHADS2 variable into its individual scores, a Cochran-
Armitage trend test was performed to compare warfarin
usage based on CHADS2 score, with a p value of .05 sug-
gesting a statistically significant difference. All statistical
analyses were performed using SAS software (version 8.2).
Comparing Prior Studies Investigating Warfarin 
Underutilization
A systematic literature search using the MEDLINE compu-
terized database was performed (January 1, 1995, to
December 1, 2005). Relevant studies were identified by
using the following keywords: "warfarin, underutilization,
coumadin, fall risk, atrial fibrillation, CHADS2, anti-coagula-
tion in atrial fibrillation, stroke risk, gastrointestinal bleed,
transient atrial fibrillation, intracranial hemorrhage, elderly".
Bibliographies of each article were reviewed to identify
additional articles. Articles relevant to the present study
were than tabulated into a table and warfarin utilization
rates were compared based on study period, health care
setting and study methodology.
Results
Of the 364 patients, 199 patients (54.6 %) received warfa-
rin. Patients who received warfarin were younger than 75
years compared to patients who did not receive warfarin
(table 1), and African American patients were less likely to
receive warfarin. Only 5 patients (1.3%) had a CHADS2Thrombosis Journal 2008, 6:6 http://www.thrombosisjournal.com/content/6/1/6
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score of zero and 34 patients (9.3%) had a CHADS2 score
of 1, suggesting a moderate-to-high risk of thromboembo-
lism in the study population. There were no significant
differences in the proportion of patients with prior hyper-
tension, stroke, cardiac disease, or diabetes between
patients prescribed warfarin and those not receiving anti-
coagulation. As shown in Table 1, the mean overall
CHADS2 score was higher in patients not receiving warfa-
rin compared to patients on warfarin therapy (3.2 ± 1.3 vs.
2.8 ± 1.3, p < .004). Also, there were more patients with a
CHADS2 score of 3 or greater in the cohort not on warfarin
therapy, compared to the group on warfarin therapy (70%
vs. 56%, p= 0.004). A detailed review of medical records
revealed documented reasons for not prescribing warfarin
in 83% (137/165) of patients not receiving warfarin. Prior
or recent gastrointestinal bleeding was the most often
cited contraindication to warfarin therapy; with other per-
ceived reasons listed in Table 2. Only 7.1% (26/364)
patients did not have a documented reason for warfarin
non-use.
Table 3 compares the prior studies that have examined
warfarin utilization in AF patients. Warfarin utilization
rates very between 38%–s61% in the larger population
studies that employ ICD-9-CM (The International Classi-
fication of Diseases, Ninth Revision, Clinical Modifica-
tion) diagnostic codes, administrative or billing databases
for assessing warfarin use while the rates drop signifi-
cantly lower in the smaller patient cohort studies that
review medical charts and account for reasons for warfarin
nonuse.
Discussion
The present study conducted at a single tertiary care center
shows that 45% of AF patients did not receive antithrom-
botic therapy with warfarin. However, individual medical
chart review revealed that 83% of patients not prescribed
warfarin had a real or perceived documented reason for
warfarin nonuse cited by the healthcare provider. After
taking these factors into account, only 7.1% of ideal can-
didates for warfarin therapy were not receiving warfarin
therapy.
McCormick et al [12] showed an overall warfarin utiliza-
tion of 42% (180/429), but a further detailed chart review
of 83 "ideal warfarin candidates" demonstrated 75% war-
farin use in those with no potential warfarin contraindica-
Table 1: Characteristics of Patients with AF classified based on Warfarin Use
Characteristics Received Warfarin n = 199 Did Not Receive Warfarin n = 165 p value
Age, years, mean 76.3 ± 11.3 81.3 ± 10.3 < 0.001*
Age 75 ≥ y, n (%) 125 (62.8) 134 (81.2) < 0.001*
AA Race, n (%) 74 (37.2) 82 (49.7) 0.016*
Women, n (%) 76 (38.2) 79 (47.9) 0.063
CAD, n (%) 92 (46.2) 87 (52.7) 0.217
Mean CHADS2 Score ± S.D 2.8 ± 1.3 3.2 ± 1.3 0.004*
CHADS2 Score- 3 or greater (%) 111 (56) 116 (70) 0.004*
Chads2 Score
No. of points, n (%)
0 3 (1.5) 2 (1)
1 22 (11) 12 (7)
2 63 (32) 35 (21)
3 59 (30) 58 (35)
4 32 (16) 28 (17)
5 15 (7.5) 22 (14)
6 5 (2.5) 8 (5)
Heart Failure, n (%) 120 (60.3) 103 (62.4) 0.679
Diabetes, n (%) 68 (34.2) 66 (40.0) 0.251
Hypertension, n (%) 179 (90.0) 149 (90.3) 0.911
Prior Stroke, n (%) 47 (23.6) 43 (26.1) 0.591
Abbreviations: AA- African American, CAD- Coronary Artery Disease, CHADS2- C-cardiac failure, H-hypertension, A-age > 75 years, D- diabetes 
mellitus, S- stroke, S.D- Standard deviation
*Statistically significant, p < 0.05
Table 2: Physician's Perceived Reasons for Not Initiating 
Warfarin Therapy (N = 137)
1. History of Gastrointestinal Bleed - 39 (28%)
2. Transient/Secondary AF - 30 (22%)
3. Fall Risk - 23 (17%)
4. Patient preference - 19 (14%)
5. History of Non-Gastrointestinal Bleed - 11 (8%)
6. Poor Patient Compliance - 8 (6%)
7. Coagulopathy - 5 (4%)
8. Miscellaneous - 2 (1%)Thrombosis Journal 2008, 6:6 http://www.thrombosisjournal.com/content/6/1/6
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tions. Similarly, Weisbord et al [13] and Hylek et al [8]
showed a dramatic decrease in warfarin underutilization
rates after employing chart reviews and excluding patients
with documented contraindications to warfarin therapy.
Further, in a recent report Waldo et al [9] from the
NABOR (National Anticoagulation Benchmark Outcomes
Report) Committee studied warfarin underutilization in
hospitalized patients with AF and showed initial warfarin
underutilization rates of about 54.4%, but in the high-risk
stroke AF patients, after taking bleeding considerations
into account, the underutilization was reduced by 10%.
Review of other prior studies examining AF underutiliza-
tion (table 3) cumulatively suggest that published rates of
warfarin underutilization are highly influenced by the
rigor used to review patient charts, and that administrative
database reviews can underestimate the proportion of
patients with real or perceived relative contraindications
to warfarin use.
As shown in table 1, a greater percentage of patients in the
non warfarin group had a CHADS2 score of 3 or greater
(70% vs. 56%, p = 0.004). This is of extreme concern as AF
patients with high calculated stroke risk are not being
treated with warfarin therapy due to one or more physi-
cian perceived contraindications. Primary documented
reasons for warfarin non-use in our study included history
of GI bleeds (39/165), transient/secondary AF (30/165),
and fall risk (23/165).
History of GI bleed accounted for 29% (39/137) of the
warfarin candidates not on warfarin therapy in our study.
Our finding is in agreement with prior studies, that physi-
cians are less likely to initiate antithrombotic therapy in
patients with a history of GI bleed.[14,15] This concern is
understandable; considering persons on warfarin therapy
are not only more likely to develop major GI tract bleed-
ing (2-fold higher) but also, this risk also increases with
age. [16,17] Yet, Man-Son-Hing and Laupacis showed in
their study [18] that in order not to benefit from warfarin
therapy, the person must have a significantly high risk of
upper GI tract bleeding (> 10.4% per year) or a stroke risk
less than 2.4% per year (patients with AF carry a 4.5%
annual stroke risk). They further suggested a treatment
model to help guide antithrombotic therapy in AF
Table 3: Comparison of Patient Selection Methods in Prior Studies Examining Warfarin Utilization in AF Patients
Study Period Author Setting Patient 
Selection for 
AF based on
Patient 
Population 
Size
Warfarin 
Utilization %
"Warfarin 
Candidates" 
not on 
Warfarin %
Method of 
determining 
Warfarin 
Utilization
1995–1998 Weisbord et 
al.13
VA Medical Chart 
review
1289 65 3.5 Medical Chart 
reviewed by 
physicians for 
documented 
contraindication
1996–1997 Go et al.11 Large HMO ICD-9-CM code 13428 55 37.9 Pharmacy 
database, 
Outpatient INR, 
ICD for 
"Coumadin 
Therapy"
1997–1998 McCormick et 
al.12
Long term Care 
Facility
Medical Chart 
reviewed for 
EKG diagnosis or 
documentation 
by physician
429 42 32 Warfarin 
prescriptions, 
INR, Physician 
Notes
2000–2002 Waldo et al.9 Teaching, 
community and 
VA hospitals
ICD-9-CM code 945 54 22 ICD-9 & Medical 
chart review
2000–2005 Darkow et al.7 HMO ICD-9-CM code 12539 39 61 Unable to obtain
2001–2003 Hylek et al.8 Urban teaching 
hospital
Electronic 
medical chart 
review and ECG 
verified AF
405 51 2 Electronic 
medical chart 
review for 
physician cited 
reasons for 
warfain non-use
2004–2005 Our Study Single Tertiary 
Care Hospital
Medical Chart 
review and 
physician 
confirmation of 
AF by EKG
364 54 7.1 Medical chart 
reviewed by 
physicians for 
documented 
contraindicationThrombosis Journal 2008, 6:6 http://www.thrombosisjournal.com/content/6/1/6
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patients with a history of upper GI tract bleeding. As lower
GI tract bleeding was not included in the model, Beyth
suggested in the same study, that a treatment model to
help guide physicians should attempt to include other fac-
tors known to augment the risk for both upper and lower
GI bleed such as older age, non-steroidal anti-inflamma-
tory drugs, [19,20] steroid use, [21] proton pump inhibi-
tors, alcohol consumption, cigarette smoking and
warfarin noncompliance. GI bleed can occur due to differ-
ent reasons and in some cases can be related to a specific
causative factor or event that led to the bleed. It is reason-
able to think that removal of the causative factor or treat-
ment should not place the patient at risk for future
bleeding or make them ineligible for warfarin therapy,
especially if the therapy is to occur years later. Future
research should examine this specific cohort closely to
help better identify potential patients who could other-
wise benefit from warfarin therapy.
The second most common reason for not starting warfarin
therapy was transient or secondary AF. It is clear from the
current literature that this group of patients should be
treated as AF patients and be given warfarin therapy.[9,22]
To correct this oversight and diminish the number of such
cases, healthcare providers must be made aware of warfa-
rin therapies and educated in depth.
Fall risk was the third most commonly reported reason in
our patient cohort for not prescribing warfarin, and as
falls are associated with the elderly population [23-25] in
which AF is highly prevalent, this is particularly a note-
worthy finding. There is much ambiguity involved when
a patient is labeled as "fall risk". [26] As shown in prior
studies, patients are often not started on anti-coagulation
for fear of the bleeding risk that is associated with
falls.[27] We agree that this is a difficult topic to assess, as
fall or neurological illness histories not routinely investi-
gated or taken into account, but such histories are highly
variable and subjective, based on the healthcare provider
and the patient. Despite all these issues, we believe this is
a key area for clinical improvement. Previous studies have
cited fall risk and intracranial hemorrhage as the major
reasons for not initiating anticoagulation in AF patients,
especially the elderly.[23,27,28] The recent Birmingham
Atrial Fibrillation Treatment of the Aged (BAFTA) trial
[25] showed that even in an older AF patient group, war-
farin decreased fatal stroke (1.8% per yr vs. 3.8% per
year), and did not increase intracranial hemorrhage risk
(1.4% per year vs. 1.6% per year) compared to aspirin
therapy. Moreover, Gage et al [24] demonstrated that
while older patients are at high risk for falls and carry an
increased risk for intracranial hemorrhage, these patients
also have a higher stroke risk, and therefore would likely
benefit from anticoagulant therapy. These studies empha-
size the point that fear of intracranial hemorrhage might
be overestimated in this patient cohort. Indeed, a recent
study by Jacobs [29] showed that effective management of
warfarin can be achieved in the elderly by careful atten-
tion to these issues. Healthcare institutions should also
consider employing objective methods to identify
patients at fall risk by utilizing screening forms and taking
patient, physician, and social factors into consideration.
This study has limitations inherent to a retrospective chart
review. Our study was confined to a single center, and
practice patterns might vary at other hospitals. Data col-
lection regarding warfarin contraindications was limited
to the available medical record content and no pre-speci-
fied or verifiable criteria were applied to the physician-
cited contraindications for nonprescription of warfarin.
The limited sample size in the group with documented
perceived contraindications prevented further analysis to
examine the adequacy of the contraindication to warfarin
therapy.
In conclusion, our study found documented reasons for
warfarin nonuse in a majority of the patients, as after a
detailed medical chart review, only 7.1% of ideal candi-
dates for warfarin therapy were not receiving it. These
findings suggest that administrative database studies
might overestimate warfarin underutilization in AF
patients and that physician omission/error is not the pri-
mary cause of warfarin underutilization. There is an
urgent need for prospective studies to investigate relative
warfarin efficacy and bleeding risks in patients with per-
ceived warfarin contraindications, as it would help guide
healthcare providers in warfarin prescribing and conse-
quently reduce the risk of AF-related disabling strokes.
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